The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma

Experimental Hematology

Volumn 39, Issue 3, 2011, Pages 330-338

  Stewart, Helen J ^a   Kishikova, Lyudmila ^a   Powell, Fiona L ^a   Wheatley, Sally P ^a   Chevassut, Timothy J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BORTEZOMIB; CASPASE 8; DEXAMETHASONE; FIBRONECTIN; INTERLEUKIN 6; LAMININ;

APOPTOSIS; ARTICLE; BONE MARROW; CELL ACTIVITY; CELL ADHESION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINESIS; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENDOREDUPLICATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; STROMA CELL;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES;

EID: 79951955579     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.12.006     Document Type: Article

References (32)

1. Takaki T., Trenz K., Costanzo V., Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008, 20:650-660.
2. Ikezoe T., Yang J., Nishioka C., et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009, 23:1564-1576.
3. Renner A., Dos Santos C., Recher C., et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009, 114:659-662.
4. Steegmaier M., Hoffmann M., Baum A., et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007, 17:316-322.
5. Ramasamy K, Khatun H, Macpherson L, Mufti GJ, Schey S, Calle Y. Direct effect on the stroma by the conventional anti-multiple myeloma drug dexamethasone results in resistance of multiple myeloma plasma cells against therapy. Sensitisation to dexamethasone by the kinase inhibitor dasatinib. American Society of Haematology Annual Scientific Meeting, Abstract 193, December 2010.
6. Stewart H.J., Guildford A.L., Lawrence-Watt D.J., Santin M. Substrate-induced phenotypical change of monocytes/macrophages into myofibroblast-like cells: a new insight into the mechanism of in-stent restenosis. J Biomed Mater Res A 2009, 90:465-471.
7. Tategu M., Nakagawa H., Sasaki K., et al. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor. J Genet Genom 2008, 35:215-224.
8. Dezorella N., Pevsner-Fischer M., Deutsch V., et al. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 2009, 315:1904-1913.
9. Poder K., Chauhan D., Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009, 23:10-24.
10. Strebhardt K. Multifaceted polo-like kinases drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010, 9:643-660.
11. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14:559-570.
12. Winkless J., Alberts G. Differential regulation of polo-like kinases 1,2,3 and 4 gene expression in mammalian cells and tissues. Oncogene 2005, 24:260-266.
13. Zimmerman W., Erikson R. Polo-like kinase 3 is required for entry into S phase. Proc Natl Acad Sci U S A 2007, 104:1847-1852.
14. Dai W., Liu T., Wang Q., Rao C.V., Reddy B.S. Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int J Oncol 2002, 20:121-126.
15. Habedanck R., Stierhof Y.D., Wilkinson C.J., Nigg E.A. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 2005, 7:1140-1146.
16. Drewinko B., Alexanian R., Boyer H., Barlogie B., Rubinow S.I. The growth fraction of human myeloma cells. Blood 1981, 57:333-338.
17. Sebastian M., Reck M., Waller C.F., et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010, 5:1060-1067.
18. Lens S.M.A., Voest E.E., Medema R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010, 10:825-841.
19. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 2009, 281:128-133.
20. Basak G.W., Srivastava A.S., Malhotra R., Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009, 10:345-346.
21. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
22. Zhang X.G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74:11-13.
23. Negri J.M., McMillin D.W., Delomore J., et al. In vitro anti-myeloma activity of the aurora kinase inhibitor VE-465. Br J Haematol 2009, 147:672-676.
24. Macůrek L., Lindqvist A., Lim D., et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
25. Shi Y., Reiman T., Li W., et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007, 109:3915-3921.
26. Chng W.J., Braggio E., Mulligan G., et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008, 111:1603-1609.
27. Evans R.P., Naber C., Steffler T., et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008, 140:295-302.
28. Hose D., Rème T., Meissner T., et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009, 113:4331-4340.
29. Evans R., Naber C., Steffler T., et al. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008, 49:559-569.
30. Wang X., Sinn A.L., Pollok K., et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 2010, 150:313-325.
31. Görgün G., Calabrese E., Hideshima T., et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010, 115:5202-5213.
32. Chopra P., Sethi G., Dastidar S.G., Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Exp Opin Invest Drugs 2010, 19:27-43.